Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
about
Disaggregation and invasion of ovarian carcinoma ascites spheroidsAscites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancerThe human plasma lipidomeStiffness dependent separation of cells in a microfluidic device.Role of malignant ascites on human mesothelial cells and their gene expression profilesThe prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.ATX-LPA receptor axis in inflammation and cancer.Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells.Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancerTargeted ovarian cancer treatment: the TRAILs of resistance.Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancersElevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.Absence of constitutive EGF receptor activation in ovarian cancer cell lines.Profiling of cytokines in human epithelial ovarian cancer ascites.Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosisA transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cellsAssessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells.New strategies for the treatment of ovarian cancer.Characterization of a novel silencer element in the human aromatase gene PII promoter.The Unique Molecular and Cellular Microenvironment of Ovarian CancerA three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells.The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin.Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad.Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2).Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction.Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity.
P2860
Q25257559-15EAFC01-D2DE-4762-A975-D0D302777A68Q26746203-CCD9C5D7-EF07-4BD5-A6A0-AE235233BD46Q26830940-84C66938-1FB5-4090-8421-AF113E4F7DE6Q27305069-D812348D-4EDE-4F0C-9071-FECB00FAA3FCQ33559857-6746F711-BC9F-409B-80E5-7AF140F8DBB4Q33650479-1D4330FC-BEC6-493F-9C88-7A26C2401BE7Q33914512-177EFA49-FD35-4E24-B334-37A27D828507Q34199719-BE255FA1-7195-4065-8E7C-5F6C9C395F2FQ34335443-1A3CDF90-5255-4035-8BAE-ED5B19C7E139Q34441724-0ED7B9BA-0F80-4CF5-A60C-D32CE9DB193FQ34517736-858125F4-3828-4144-87F5-45E914323ECEQ35609438-B0F03CEE-991C-43CD-B32D-F54A25B5FB2EQ35677625-E1E2709D-EF2F-4A20-9631-825EFBD73827Q36117436-4FCB4D22-1FB2-43EC-B979-31D76B6A6D5BQ36135788-D40E9CB5-09EB-4A4D-BF71-F1191FABC1DBQ36206483-57770CC3-5658-4CE8-8301-FB14AD740164Q36478459-39C3FF81-EFA9-48C3-B189-A696AD6C884DQ36929682-38E80708-BA9D-4169-BEF3-F2F2C28248D9Q37022535-95417AC8-3536-4C33-841C-3F82214BB26AQ37196532-08386397-B6BB-4CF4-887C-C29F794DBA54Q37289059-23EE6E18-4331-49E4-B76D-031B3484D6CBQ37316669-C0D1EA15-D652-4374-A79A-605DB7BB9941Q37513779-656F318E-D41D-4A27-B740-4E0E050CB1B6Q38180769-2BF4B659-34F3-4550-913C-D60DBF193276Q38307923-0ACAC6DA-F0BF-4BCA-86E3-595B00A69306Q39169603-FF103DF9-96D4-4552-9C4E-9D70C07D308FQ39185534-2EF51D72-6C84-4186-AB24-C9CE9177C2A0Q39348777-7A66E7EF-8D51-4E18-A841-CC43C491CD41Q39411440-9C05963B-C515-4737-B6C6-5EDCE9BFF2A5Q39978113-EF7D0BFA-4359-46AD-823C-799D52425F1EQ40609797-F8FF13E5-8A12-47FD-A2C8-46B427D11D02Q41693287-4C4F37BA-F375-4E7C-8A0F-FDBE9BF82EF9Q44719653-E9C12F10-5BB3-4819-BD71-986664A5B698Q47201278-62D656E6-D6CD-40A8-8C83-9481F8078542Q47313086-740C44E8-F0A1-4918-8B85-36EC911C41A7Q49724715-F18E474F-97E4-4272-8987-A6FF6688D065Q52365303-BA4E052B-FAFF-4D1F-8150-357A9D6B8CD7Q53668906-5AEA546B-B7FF-480F-94D0-69C5AC1EC203Q55438393-E257FD26-B5AD-4062-AB51-9886E59CFC61
P2860
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@ast
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@en
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@nl
type
label
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@ast
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@en
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@nl
prefLabel
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@ast
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@en
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@nl
P2093
P2860
P4510
P921
P356
P1476
Ascitic fluid from human ovari ...... ovarian adenocarcinoma cells.
@en
P2093
P2860
P304
P356
10.1172/JCI114784
P407
P577
1990-09-01T00:00:00Z